In this study we identified and characterized a novel cyclic peptide that facilitates the rapid transportation of conjugated molecules across the epithelial layer of the small intestine. The peptide was initially selected from phage display libraries using a large animal experimental model which employed consecutive in vitro and in vivo panning. The procedure was designed to enrich for peptides that facilitated transcytosis across the intestinal epithelium into the intestinal afferent lymphatic system. A small set of peptides was repeatedly isolated using this selection method, 2 however the cyclic nonamer CTANSSAQC, 13C dominated. The activity of the putative targeting peptide C13 was then verified using a mouse model. These experiments showed that the 13C peptide as well as macromolecules conjugated to it were rapidly transported across the intestinal mucosa into distinct subsets of epithelial cells and CD11+ cells located in the lamina propria and Peyer's Patches. Significant amounts of intact protein could be delivered into the systemic circulation after rectal and nasal application. Thus, peptide 13C is regarded as an attractive carrier candidate for mucosal delivery of large molecules. The preferential targeting to distinct intestinal cells may be utilized to deliver active biological drugs for the effective control of diseases of the gut.
INTRODUCTION
While most diseases including inflammatory diseases or tumors are localized and display tissuespecific features, drugs to combat these diseases are usually applied via systemic routes. This implies a potential loss of treatment selectivity and efficacy. Similarly, vaccines elicit quantitatively and qualitatively different immune responses depending on the route of application. For example, gastrointestinal administration of proteins, in the absence of adjuvants, preferentially induces immunological tolerance ("oral tolerance") 1 , but adjuvant-including enteric vaccines are superior in inducing IgA responses which are important to prevent infections with targeting [13] [14] [15] and receptor identification 16, 17 . Extensive screening of phage display libraries has also been used to identify ligands that facilitate translocation across the mucosa of the gastrointestinal tract 18 or binding to and transport via M cells 19, 20 or goblet cells 21, 22 .
The aim of this study was to identify and characterize novel peptides that are actively transcytosed via the intestinal mucosa. These peptides were selected from phage display libraries by consecutive in vitro and in vivo panning using a large animal experimental model. The selection method led to the identification of the cyclic nonamer CTANSSAQC (13C) peptide. The activity of this putative targeting peptide was then verified using a mouse model. We found that 13C as well as 13C-conjugated macromolecules were rapidly transcytosed via the intestinal mucosa in both sheep and mouse models. Peptide-protein conjugates were taken up by, and enriched in, both epithelial and dendritic cells located in the lamina propria and PP and additionally delivered into systemic circulation via the lymph. Thus, peptide 13C is regarded as an attractive carrier candidate for the mucosal delivery of proteins or other macromolecular agents in sheep, mice and possibly other animals.
EXPERIMENTAL SECTION

Animals.
All sheep experiments were conducted under the approval of the Animal Ethics Committee of the Wallaceville Animal Research Centre, New Zealand.
All mice experiments were performed in accordance with the European directive on the protection of animals used for scientific purposes and the respective German animal welfare legislation. Female BALB/c mice were purchased from Charles River and used at 8 to 10 weeks of age. Mice were maintained under specific pathogen free conditions and randomly assigned to the different experimental groups.
Phage libraries.
The cyclic Ph.D. 
Panning procedures
In vitro binding of phage to sheep intestine
For selection of phage binding in vitro to sheep tissue, both libraries were panned independently.
A 10 cm segment of the jejunum, including a PP, was removed from sheep at necropsy, washed with PBS and tied off at both ends. The lumen was partly filled with 10 µl of an aliquot of a phage display library diluted in 5 ml of PBS supplemented with a complete protease inhibitor cocktail (Roche, Basel, Switzerland). The segment was incubated 30 min slowly rocking on ice.
The content was then discarded and an approximately 3 cm segment containing a PP isolated.
This segment was cut open on the minor curvature, repeatedly washed with cold PBS and transferred to an E. coli K91/Kan culture growing at the mid-log phase at an OD600 of 0.5 to enable tissue associated phage to infect the bacteria. After 30 min, tissue was discarded and aliquot samples were taken for phage titering, while the remainder was amplified for 4.5 h at 37
°C. Amplified phage were purified by PEG/NaCl precipitation, washed in PBS and titered using standard protocols. The amplified phage were then subjected to a similar second selection procedure using freshly prepared tissue. PP tissue was isolated and washed >10 times in cold PBS / 5mM EDTA prior to recovery of phage.
In vivo binding of phage to sheep intestine and PP
For in vivo panning, phage preselected by in vitro panning were amplified and further independently subjected to an in vivo panning procedure in sheep. For all in vivo panning experiments input phage were supplemented with complete protease inhibitor and chloroquine (500 mg) was injected i.m. to temporarily inhibit the processing of antigens within antigen presenting cells 23 . Three approximately 30 cm long intestinal segments containing at least one PP were accessed by laparotomy of an anaesthetized sheep. The ingesta were flushed out by injection of 20 ml of water and the ends clamped off. An aliquot of amplified in vitro preselected phage library diluted in 5 ml PBS was injected into loops for 15, 30 or 60 min. The animal was euthanized by barbiturate overdose (sodium pentobarbitone 125 mg/kg), intestinal segments removed, flushed with PBS / 5mM EDTA and rinsed several times with 0.2M glycine pH 2.2. Glycine-washes were used to remove any mucus, or mucus-and epithelium-bound phage from the tissue. PP tissue was isolated from each of the washed segments, washed again repeatedly in glycine, processed by dissection into small pieces and partly solubilized in PBS 1%
CHAPS prior to incubation in E. coli and phage titering and amplification of phage as above.
Recovery of phage from sheep intestinal lymph and PP
Amplified phage were pooled across sampling time points but pools derived from the cyclic or linear phage library were independently subjected to one modified in vivo selection procedure, where transcytosed phage were recovered from afferent lymph of sheep via lymphatic cannulation 24, 25 . The drainage of afferent lymph was visualized by injection of trypan blue into the sub-serosa of the intestine, and a pseudo-afferent lymph vessel was cannulated by insertion of a small catheter. Up to three approximately 30 cm segments of the intestine with at least one PP in the drainage region of the catheter were prepared followed by luminal challenge with an aliquot of pre-selected amplified phage as above. Lymph was collected continuously for up to 6 h after challenge, into ice-cooled collection tubes containing heparin as an anti-coagulant. The animals were then euthanized and intestinal segments removed, PP tissue isolated and processed as above. Cells were separated from lymph plasma by centrifugation, solubilized in PBS/1%
CHAPS and individual samples, including a pooled lymph sample, used to infect the E. coli host strain. Elution samples were taken after 30 min for titering, while the remaining phage were amplified as above.
All samples derived from cyclic and linear phage libraries were then pooled and subjected to two additional in vivo selection procedures in sheep fitted with an afferent lymphatic cannula as above.
In vivo validation for specificity of the selected peptide phage
To test whether the peptides selected for the ability to promote phage transcytosis were indeed preferentially transcytosed from the intestinal lumen into the lymphatic system of sheep, six clones that were identified in previous experiments (2L, 4L, 13C, 26PP, 28PP and 38PP) were individually amplified and then combined in equal amounts. 
Identification of individual phage clones.
Samples were titered on LB/IPTG/Xgal plates that enabled differentiation between wild type and library phage plaques using the E. coli strain K91/Kan/BK in the standard procedure recommended by New England Biolabs. Individual library phage plaques were picked from elution samples (details are given in Tables 1 and 3) , re-amplified and subjected to M13 phage DNA extraction using a commercially available kit (Qiagen, Venlo, Netherlands). DNA was sequenced using the 96gIII sequencing primer as recommended by New England Biolabs and a bioinformatics analysis performed using a basic BLAST search (BLASTp).
Synthetic peptides and coupling procedures.
For sheep experiments, a selection of the identified peptides (2L (CPTSHHRAC), 13C
(CTANSSAQC), 28PP (CDPSPSRHC) and two versions of a scrambled 13C peptide (13Csc (CSNAQATSC or CASQNSTAC), which served as controls) were synthesized with a purity of For analysis of protein uptake in mice, several different streptavidin conjugates were prepared.
Biotinylated peptide was added in a 10-fold excess to streptavidin solution and incubated at room temperature for one hour. The peptide-streptavidin conjugate was then purified by size exclusion 
Analysis of peptide transcytosis in sheep.
Afferent intestinal lymphatic cannulation was performed in sheep as described previously 24 .
Sheep were additionally fitted with a catheter (inner diameter 1.2 mm) that reached into the lumen of the jejunum and was anchored into the intestinal wall and exteriorised through the same abdominal opening as the lymphatic cannula. The intestinal catheter was placed in a part of the jejunum from which lymph was likely to drain into the cannulated lymphatic vessel, although lymph draining from other sites could not be excluded. After full recovery from surgery, 50 µg of radiolabelled peptide in 5 ml PBS supplemented with complete protease inhibitor was administered directly into the intestinal lumen. Peptides 13C, 28PP, 2L and 13Csc were administered consecutively, every third or fourth day once radioactivity had declined to near background levels depending on how long the lymphatic cannula remained patent. Each peptide was given to 3 -4 different animals (details are given in Supplementary Figure 1) . Lymph was collected continuously and sampled for 30min prior to application, then at time points 30min, 1h, 2h, 3h, 4h and 6h after administration. Radioactivity was measured at all collection time points in 100 µl whole lymph, cells from 1 ml of lymph washed once in PBS, 100 µl of lymph plasma and streptavidin precipitate of 1 ml lymph plasma. During the experiment it became obvious that radioactivity was lost during cell washing and consequently measuring the activity of cells separated from 1 ml lymph was included.
Intact biotin-tagged radioactive peptide was precipitated from lymph plasma using streptavidin agarose (SIGMA, St. Louis, MO). Lymph plasma was obtained by centrifugation of whole lymph for 5 min at 400 g. Streptavidin agarose was washed in PBS immediately prior to use, then 100 µl mixed with 1ml of lymph plasma, incubated for 30 min on ice, pelleted and washed before measuring radioactivity with a gamma counter.
7.
Visualization of peptide and protein uptake in mouse intestine. For immunohistochemical staining, the sections were warmed up to room temperature and rehydrated in PBS. All washing steps were performed using PBS containing 1% BSA and 0.1% Tween20 (SIGMA). Blocking buffer additionally contained 10% rat serum. After 20 min incubation with blocking buffer, the sections were stained with anti-CD11c mAb (N418; produced in-house) conjugated Alexa to Fluor®647 for 1 h at room temperature and washed twice. After staining, the slices were mounted with DAKO mounting medium containing DAPI (SIGMA). To examine the staining, a LSM 710 confocal microscope (Carl Zeiss, Jena, Germany) was used and photomicrographs were taken using the software Zen 2011 (Carl Zeiss MicroImaging GmbH, Göttingen, Germany).
Analysis of transcytosis of peptide-protein constructs.
Balb/c mice were dosed orally, rectally or nasally with radiolabelled peptide-streptavidin-[I-125] constructs. For oral dosing, mice were gavaged with 0.5 mg in 200 µl PBS using a feeding needle. For rectal dosing, mice were injected rectally with 0.5 mg in 200 µl PBS using an umbilical catheter with a diameter of 0.5 x 0.8 mm that was introduced into the rectum. For nasal dosing mice were anesthetized with dexdomitor (0.4 mg/ml, Pfizer, New York City, NY) and isoflurane (Forene®, Abbott, Chicago, IL) inhalation. After intra-nasal application of 0.05 mg construct in 20 µl PBS, mice were injected with anti-mepazole (2 mg/ml, Pfizer). After 4 h incubation with the peptide-streptavidin construct the mice were sacrificed, blood, urine and various organs (thymus, stomach, small intestine, large intestine, lung, liver, kidneys, heart and skin including the fur) were sampled. Blood cells were obtained by centrifugation, blood plasma was treated with Trichloroacetic acid (TCA) to separate degraded protein or free radioactivity from intact labeled protein (TCA-soluble plasma fraction). Radioactivity in the blood compartments was computed for a total blood volume of 1.5 ml per mouse (60 ml/kg). All samples were analyzed using a gamma counter (Wallac, Turku, Finland).
Statistical analysis.
Mixed modelling was used for data analysis of peptide transcytosis in sheep, with individual animals specified as random effects and peptides as fixed effects, using the REML (Residual Maximum Likelihood) criterion. The data consisted of LOGe AUC (area underneath curves over time) corrected for the value at hour 0 as a covariate, testing for differences between the four peptides. Values for streptavidin precipitated lymph samples were included in the analysis. Data were described as LOGeMeans (the mean of the LOGe AUC for each peptide, SE, minimum and maximum. Statistically significant differences were observed at p<0.05.
Data of protein transport in mice are presented as means ± SEM. Significance was determined with unpaired student's t test after confirming normality distribution by D'Agostino & Pearson omnibus normality test. Differences were considered as statistically significant with p≤0.05 (*), very significant with p≤0.01 (**) and extremely significant with p≤0.001 (***). Two additional panning procedures involving afferent lymphatic cannulation with amplified preselected phage pooled across compartment origin and the collection time points resulted in an increase in recovered phage. The titer of phage recovered from PP was 10 6 -10 7 pfu/ml, from the lymph pool 10 5 -10 6 pfu/ml, and from the lymphatic cells 10 4 -10 6 pfu/ml over the first two hours of sampling, with little recovery at the later sampling time points. More than 30 individual phage clones recovered from the three different compartments were subjected to sequencing following each of the final two in vivo transcytosis enrichment cycles.
Selection for peptides promoting intestinal transcytosis of phage
As shown in Table 1 , only nine different peptides were found to be displayed on the selected phage because several peptides were represented in multiple clones. Three of the peptides, 2L, 4L and 13C were found following both rounds of transcytosis enrichment, usually in the same compartment. Bioinformatics analysis of the nine peptides for homologues found no compelling matches in protein databases containing non-redundant protein sequences. Analysis of the frequency of amino acids in different positions revealed that their distribution was not random.
Constraint peptides tended to have an over-representation of H, S and P but E, F, W, Y and V
were not present.
In vivo validation for specificity of the selected peptide phage
Preferential transcytosis of selected library phage was assessed in the presence of a 2x10 4 fold excess of wild type phage in an afferent cannulation experiment. Phage were isolated from lymphatic cells (~10 5 pfu) and lymph plasma (~10 6 pfu). Between 1% and 40% of phage recovered from the three compartments at 30 min and 2 h post-injection were non-wild type,
demonstrating an approximately 10 2 -10 4 fold enrichment of putative transcytosis peptidedisplaying phage compared to wild type phage ( Table 2 ). Much greater enrichment was observed at the 30 minute as compared to the 2 hour time point, further suggesting that the peptidedisplaying phage were entering by a facilitated transcytosis process. Sequence analysis was performed to determine the relative abundance of phage displaying the six different putative transcytosis peptides obtained from the three compartments following in vivo selection (Table 3) . Two cyclic displayed peptides dominated the selection, 13C and 28PP, representing 36 of 40 clones sequenced. given a selection of library phage clones in the presence of 2x10 4 fold excess of wild type phage.
A strong selection for clones 13C and 28PP was found. Transcytosis of intact peptide 13C was higher than for 2L and 13Csc (p≤0.001), and 28PP was higher than for scrambled 13C (p=0.027) as determined by REML analysis. In summary, 13C
Frequency of isolations
peptide and, to a lesser extent, 28PP peptide display enhanced transcytosis from the lumen of the gut into the lymphatic system in a sheep model. 
Visualization of intestinal 13C peptide uptake in vivo
Transcytosis of the 13C peptide was further verified in a mouse model by confocal microscopy.
Uptake of 13C-FITC into small intestinal epithelial cells as well as cells within the villi was detected as early as 5 min after luminal delivery of the construct (Figure 2 A, B) . In contrast, very little or no uptake of the control peptide 13Csc-FITC was observed with most of the material being trapped in the mucus of the gut lumen (Figure 2 C, D) . Furthermore, CD11c positive cells, most likely dendritic cells, located in the villi in close proximity to the epithelium were found to be positive for 13C. We conducted 13C uptake studies to reveal if a saturating receptor-ligand interaction is involved.
Pre-expose of the intestinal mucosa with unlabeled peptide did not block the uptake of labeled peptide. The 13C-FITC construct was found inside the villi of the small intestine with a cellular distribution and visual fluorescence intensity similar to the previous experiments in which preincubation with unlabeled 13C peptide was omitted (Figure 2 E, F) .
Peptide 13C facilitates protein uptake
Peptide 13C facilitated mucosal transcytosis both as a peptide and when expressed on M13 phage (size: 7 x 900nm; equivalent to a MW >1x10 7 ). We next tested whether the peptide would promote the delivery of protein across the mucosal barrier. We used fluorescent streptavidin as a model protein which was coupled to biotinylated peptide 13C. In order to visualize the transcytosis of 13C-protein and control 13Csc-protein, the biotinylated peptides were coupled to fluorescently labeled streptavidin and injected into the intestinal lumen simultaneously ( Figure   3 ). 
Determination of systemic delivery of a 13C -protein construct
We next tested if peptide 13C would improve the delivery of proteins into the systemic circulation. Radiolabelled 13C and 13Csc constructs were given either orally, rectally, or nasally.
Four hours after administration, the fraction of radioactivity in blood cells and blood plasma was measured. The background level of total radioactivity in the TCA-soluble plasma fraction ranged between 0.4-1.8% (data not shown). Our panning strategy involved the independent selection of both a conformationally constrained and a linear phage display library, initially in vitro and then in vivo in a sheep model. These preselected libraries were then combined and further selected in vivo in an effort to select for phage that were transported into the lymphatic system directly draining from the small intestine.
Interestingly, these additional panning steps resulted only in the selection of several cyclic peptides, suggesting that disulphide-bonded cyclic peptides form superior transcytosis ligands. It may be that the disulphide bond stabilizes the peptide and / or makes it more resistant to proteolytic degradation and thus is superior in a harsh environment such as the intestine of animals.
We established that the transcytosis of the ligands is not due to non-specific transportation of phage across the mucosa 27 , as the selected transport of library phage was several orders of magnitude greater than that of wild-type phage. Furthermore, in contrast to a study in rats where single peptides were identified 18 , we found that several of the transcytosed peptides were identified repeatedly, which provides further evidence for specific enrichment. This is supported by the fact that we found transcytosis into lymph occurring within 30 min after intestinal delivery of selected library phage. Rapid transportation of library phage was previously observed in a study in rats in which phage were recovered from tissues such as spleen, liver or kidney soon after injection into the jejunum 21 . Taken together these results provide strong evidence that our panning procedure resulted in the selection of specific transcytosis reagents.
We next conducted experiments to establish which of the selected peptides would be the most effective transcytosis ligand. Three peptides identified in the phage panning were synthesized and then inoculated directly into the otherwise unmodified small intestine of sheep. Inoculation into the intestine was used to prevent potential degradation in the rumen and abomasum. To enable identification in the lymph in ex vivo samples, each of the synthetic peptides was tagged with biotin on the amino terminus and radioactively-labelled tyrosine at the carboxyl terminus.
Detection of intact peptide involved binding to a streptavidin matrix via the biotin tag, followed by measurement of the radioactive label. To our knowledge this is the first report of an intact peptide that is selectively transcytosed into intestinal lymph from a fully functional small intestine. The recovery of significant amounts of synthetic peptides from lymph soon after inoculation (peak levels were detected from 30 min to 1 h followed by a constant decline) compared to a scrambled control peptide confirmed that preferential transcytosis has occurred.
We found that peptide 13C outperformed the other two peptides tested. Consequently we used 13C in follow up mouse studies to confirm the efficacy of the trans-mucosal delivery of proteins in a second animal model. Interestingly a phage display study in rats identified a nine amino acid long peptide (CSK; CSKSSDYQC) which increased uptake via the intestinal mucosa 21 . Our peptide 13C and CSK share some sequence similarities, notably the presence of a ser-ser motif. The CSK peptide was reported to be taken up primarily by goblet cells. This suggests that the two peptides share some features, but uptake is likely to involve different mechanisms. In vitro competition experiments with CSK peptide suggested a receptor-mediated uptake 21, 22 , whereas uptake of 13C constructs, as far as could be seen using fluorescence imaging, was not blocked by a 20-fold excess of free 13C peptide. As the scrambled version of 13C peptide is not transcytosed, non-specific uptake mechanisms such as pinocytosis are unlikely. One possible explanation is that 13C binds to a low affinity, but abundant, receptor which is not saturable and is only present on a subset of epithelial cells.
We also were able to re-isolate labeled 13C peptide from lymph plasma and consequently wanted to establish if 13C could be used to deliver molecules into the systemic circulation. Such an enhanced mucosal delivery of molecules into the blood system would be of significant interest for treatment with protein-based drugs. We have shown that 13C enhances uptake of radiolabeled streptavidin, and the labeled 13C-strepavidin complex could also be found in blood plasma. Thus, we investigated if 13C would facilitate the transportation of therapeutic proteins into systemic circulation. We found that 13C facilitated transportation of a protein into the systemic circulation after intra-rectal as well as intra-nasal delivery but not after oral delivery. It is possible that oral delivery of the non-protected target protein has resulted in gastric or intestinal degradation. It remains to be determined if the use of acid-resistant capsules or nanoparticles would prevent degradation and improve efficient delivery of 13C-coupled materials by the oral route.
In conclusion, this study describes a novel cyclic peptide that has functional characteristics of a transport vehicle for biomolecules. It enhances the uptake of proteins through the gut wall, promotes systemic delivery as well as accumulation in intestinal epithelial cells and dendritic cells. It therefore might find applications for oral, nasal or rectal delivery of biomolecular drugs making intravenous application procedures dispensable. Moreover, preferential targeting to intestinal cells might be useful therapeutically to deliver immunomodulatory or other agents so that they achieve more effective treatment of chronic inflammatory diseases of the gut. Whether or not 13C facilitated intestinal transportation enables the development of novel approaches for the induction of oral tolerance induction 29 , or if it could be used to develop tolerogenic vaccination procedures, is currently under investigation.
